Ironwood Pharmaceuticals, Inc.
IRWD
$3.58
-$0.09-2.45%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 361.51M | 296.15M | 338.99M | 308.52M | 317.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 361.51M | 296.15M | 338.99M | 308.52M | 317.68M |
| Cost of Revenue | 89.64M | 95.14M | 98.66M | 106.02M | 113.04M |
| Gross Profit | 271.87M | 201.02M | 240.32M | 202.50M | 204.64M |
| SG&A Expenses | 69.84M | 82.06M | 95.91M | 110.12M | 130.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 159.48M | 177.20M | 194.58M | 216.14M | 243.33M |
| Operating Income | 202.03M | 118.95M | 144.41M | 92.38M | 74.35M |
| Income Before Tax | 171.47M | 70.03M | 93.57M | 42.91M | 23.97M |
| Income Tax Expenses | 69.29M | 46.01M | 65.02M | 50.80M | 56.31M |
| Earnings from Continuing Operations | 102.18 | 24.02 | 28.55 | -7.89 | -32.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 102.18M | 24.02M | 28.55M | -7.89M | -32.34M |
| EBIT | 202.03M | 118.95M | 144.41M | 92.38M | 74.35M |
| EBITDA | 203.88M | 120.83M | 146.32M | 94.32M | 76.33M |
| EPS Basic | 0.63 | 0.15 | 0.17 | -0.05 | -0.20 |
| Normalized Basic EPS | 0.67 | 0.35 | 0.44 | 0.24 | 0.18 |
| EPS Diluted | 0.58 | 0.11 | 0.15 | -0.06 | -0.21 |
| Normalized Diluted EPS | 0.62 | 0.31 | 0.40 | 0.23 | 0.18 |
| Average Basic Shares Outstanding | 649.83M | 647.35M | 644.81M | 642.30M | 639.59M |
| Average Diluted Shares Outstanding | 683.73M | 678.01M | 675.99M | 658.46M | 640.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |